U.S. Water Utilities Stock News

NasdaqCM:LTRX
NasdaqCM:LTRXCommunications

Lantronix (LTRX) Loss Narrows To US$1.3 Million And Tests Bullish Operating Leverage Narrative

Lantronix (LTRX) has just posted Q2 2026 results with revenue of about US$29.8 million and a basic EPS loss of roughly US$0.03, alongside trailing twelve month figures showing US$116.9 million in revenue and a basic EPS loss of about US$0.24. Over recent quarters the company has seen revenue move between US$28.5 million and US$34.4 million, while quarterly basic EPS has ranged from a loss of roughly US$0.10 to a loss of about US$0.03. This keeps the focus firmly on how efficiently each dollar...
NasdaqCM:BLFS
NasdaqCM:BLFSLife Sciences

Assessing BioLife Solutions (BLFS) Valuation After Refocus On Higher Margin Cell Processing Business

Why BioLife Solutions stock is on investors’ radar BioLife Solutions (BLFS) has drawn fresh attention after refocusing on higher-margin cell-processing products and selling its evo Cold Chain business, a move that left the company with over US$125 million in cash. This shift, together with its role supplying tools for cell and gene therapies, is now central to how investors are thinking about BioLife Solutions, its risk profile, and its potential paths for capital deployment. See our latest...
NYSE:MC
NYSE:MCCapital Markets

Moelis (MC) TTM Margin Improvement To 15.4% Tests Bearish Profitability Narratives

Moelis (MC) has rounded out FY 2025 with fourth quarter revenue of US$487.9 million and basic EPS of US$1.19, setting the tone for a year in which trailing 12 month revenue reached about US$1.5 billion and EPS came in at US$3.11. The company reported an increase in revenue from US$438.7 million and EPS of US$1.27 in Q4 2024 to US$487.9 million and EPS of US$1.19 in Q4 2025, while trailing 12 month EPS moved from US$1.93 to US$3.11 over the same period. This provides investors with a snapshot...
NasdaqGS:LQDT
NasdaqGS:LQDTCommercial Services

A Look At Liquidity Services (LQDT) Valuation After Its Latest Earnings And Guidance Update

Why Liquidity Services stock is back in focus Liquidity Services (LQDT) is back on investors’ radars after reporting its first quarter results and issuing earnings guidance for the fiscal second quarter of 2026, giving the market fresh profit and EPS ranges to assess. See our latest analysis for Liquidity Services. The earnings release and fresh guidance appear to have kept interest in Liquidity Services elevated, with a 90 day share price return of 45.35% and a 3 year total shareholder...
NasdaqGS:MCRI
NasdaqGS:MCRIHospitality

Monarch Casino And Resort (MCRI) Margin Gains Reinforce Bullish Narratives Despite Modest Growth Forecasts

Monarch Casino & Resort (MCRI) has just wrapped up FY 2025 with fourth quarter revenue of US$140.0 million and basic EPS of US$1.27, while trailing twelve month figures show revenue of US$545.1 million and EPS of US$5.55, set against earnings growth of 39.3% over the past year. Over recent periods the company has seen revenue move from US$134.5 million in Q4 2024 to US$140.0 million in Q4 2025, with quarterly EPS shifting from US$0.23 to US$1.27 and trailing net profit margin sitting at 18.6%...
NYSE:ACHR
NYSE:ACHRAerospace & Defense

Archer Aviation (ACHR) Valuation Check As Midnight eVTOL Nears Certification And Infrastructure Expands

Archer Aviation (ACHR) remains in focus after filing a motion on January 23, 2026, to dismiss Joby Aero's complaint, while investors watch progress on its Midnight eVTOL program and supporting infrastructure. See our latest analysis for Archer Aviation. At a latest share price of US$6.49, Archer Aviation has seen a 26.42% 1 month share price decline and a 29.07% 1 year total shareholder return decline, although the 3 year total shareholder return is up 144.91%. This suggests long term...
NYSE:LVS
NYSE:LVSHospitality

A Look At Las Vegas Sands (LVS) Valuation After Q4 2025 Beat And Macau Margin Concerns

Las Vegas Sands (LVS) just reported its Q4 2025 results, with revenue of US$3,649 million and net income of US$395 million. The stock sold off as investors focused on weaker Macau margins. See our latest analysis for Las Vegas Sands. At a share price of US$56.94, Las Vegas Sands has seen recent momentum cool, with a 30 day share price return of 10.72% and a 90 day share price return of 12.68%, even as the 1 year total shareholder return sits at 37.43%. Recent pressure has been tied to weaker...
NasdaqCM:ECBK
NasdaqCM:ECBKBanks

ECB Bancorp (ECBK) Net Margin Expansion Reinforces Bullish Narratives Despite Premium P/E

ECB Bancorp’s FY 2025 earnings step up as margins strengthen ECB Bancorp (ECBK) has just wrapped up FY 2025 with fourth quarter total revenue of US$9.3 million and basic EPS of US$0.32, supported by quarterly net income of US$2.6 million. The company has seen total revenue move from US$7.4 million in Q4 2024 to US$9.3 million in Q4 2025, while basic EPS has shifted from US$0.18 to US$0.32 over the same period, alongside trailing twelve month net income of US$7.8 million. For investors, the...
NYSE:YOU
NYSE:YOUSoftware

Clear Secure (YOU) Valuation Check After Strong Earnings Beats And Rising Investor Attention

Why Clear Secure Is Suddenly in the Spotlight Clear Secure (YOU) has jumped up investors’ watchlists after a run of quarters where it beat both earnings and revenue expectations, drawing fresh media coverage and interest in its recent stock moves. See our latest analysis for Clear Secure. Despite a 44.92% total shareholder return over the past year, recent share price performance has cooled. The 30 day share price return is 9.30% and the 90 day share price return is 9.67%, which hints that...
NYSE:ASAN
NYSE:ASANSoftware

Is Asana’s (ASAN) AI Pivot Quietly Rewriting Its Core Monetization Playbook?

In recent days, Asana reported past progress on tightening financial discipline and raised its full-year revenue and operating margin guidance while operating in a constrained growth backdrop. A key takeaway is Asana’s push into AI-powered offerings like AI Studio and AI Teammates, which could gradually shift its business toward a more consumption-oriented model less tied to traditional seat expansion. Next, we’ll examine how Asana’s focus on AI-driven products and evolving monetization...
NYSE:DK
NYSE:DKOil and Gas

A Look At Delek US Holdings (DK) Valuation As Investor Caution Rises On Crude Volatility

Investor caution around margins and crude volatility Recent commentary on Delek US Holdings (DK) highlights investors growing more cautious as crude price swings and uncertain refining margins keep near term cash flow visibility in question. Management is responding by leaning into operational efficiency, tighter cost control, and more selective capital allocation. This approach puts the focus on existing assets rather than large scale capacity expansion for now. See our latest analysis for...
NYSE:ARE
NYSE:AREHealth Care REITs

How Investors Are Reacting To Alexandria Real Estate Equities (ARE) $1.7 Billion Impairment-Driven Net Loss

Alexandria Real Estate Equities, Inc. reported fourth-quarter 2025 results showing revenue of US$754.41 million and a net loss of US$1.08 billion, driven largely by a real estate impairment charge of about US$1.72 billion. For 2025 as a whole, Alexandria moved from net income in the prior year to a net loss of about US$1.43 billion, sharply altering how investors may assess the resilience of its real estate portfolio and balance sheet. Next, we will examine how this large real estate...
NYSE:A
NYSE:ALife Sciences

Agilent Technologies (A) Valuation Check After New Automation And AI Lab Tools Showcase

Agilent Technologies (A) is putting automation, imaging, and AI tools front and center at the SLAS2026 conference in Boston, previewing new platforms aimed at workflow efficiency and regulatory compliance in pharma and biotech labs. See our latest analysis for Agilent Technologies. Despite the automation and AI product momentum, Agilent’s recent trading has been weaker, with a 30 day share price return of a 12.17% decline and a 1 year total shareholder return of an 11.48% decline, pointing to...
NYSE:TDC
NYSE:TDCSoftware

Assessing Teradata (TDC) Valuation After Recent Share Weakness And Undervalued Fair Value Estimate

Recent share performance context Teradata (TDC) has drawn attention after a period of weaker share performance, with the stock down over the past month and past 3 months. This has prompted investors to reassess expectations and current valuation. See our latest analysis for Teradata. At a share price of US$26.75, Teradata’s recent momentum has been weak, with a 30 day share price return of a 13.96% decline and a 1 year total shareholder return of a 13.15% decline, pointing to fading...
NYSE:YETI
NYSE:YETILeisure

A Look At YETI Holdings (YETI) Valuation As Full Year Results And Manufacturing Shift Approach

YETI Holdings (YETI) is back in focus as investors look ahead to its upcoming full year results, weighing the company’s exit from manufacturing in China and its push into soft coolers and bags. See our latest analysis for YETI Holdings. YETI’s share price has had a mixed year, with a recent 27.01% 90 day share price return contrasted against a 35.80% decline over five years on a total shareholder return basis. This suggests near term momentum but a weaker long run track record. If YETI’s...
NYSE:IBM
NYSE:IBMIT

A Look At IBM (NYSE:IBM) Valuation After Strong Q4 Results And New SHIELD Program Role

International Business Machines (IBM) is back in focus after reporting Q4 results with higher revenue and net income year over year, along with a new role supporting the U.S. Missile Defense Agency’s SHIELD program. See our latest analysis for International Business Machines. IBM’s share price has pulled back recently, with a 7 day share price return of 6.26% and a 30 day share price return of 4.16%. At the same time, the 1 year total shareholder return sits at 17.34% and the 5 year total...
NYSE:LCII
NYSE:LCIIAuto Components

Is LCI Industries (LCII) Priced Right After Strong 1-Year Share Price Rebound?

If you are wondering whether LCI Industries is fairly priced or offering value right now, you are not alone. This article will walk through the key numbers that matter. The stock last closed at US$152.75, with returns of 2.3% over 7 days, 20.8% over 30 days, 22.9% year to date, 57.8% over 1 year, 49.1% over 3 years and 26.7% over 5 years. This naturally raises questions about what is already reflected in the current price. Recent coverage of LCI Industries has focused on how investors are...
NYSE:BWA
NYSE:BWAAuto Components

BorgWarner Dividend Reaffirmed As Valuation And Momentum Draw Attention

BorgWarner (NYSE:BWA) declared a quarterly cash dividend, reaffirming its regular payout to shareholders. The board approval signals continued capital return through ongoing dividend distributions. BorgWarner focuses on powertrain and eMobility solutions for global automakers, with products that span combustion, hybrid, and electric vehicle technologies. For investors watching the auto components space, dividend decisions can be especially relevant as manufacturers and suppliers adjust...
NasdaqGS:AMPH
NasdaqGS:AMPHPharmaceuticals

Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline?

Amphastar Pharmaceuticals recently reported that rising day-to-day expenses have outpaced revenue, causing its adjusted operating margin to contract by 4.3 percentage points. This margin pressure is particularly important for Amphastar, which operates with a relatively small revenue base and fewer distribution channels than larger drugmakers. We’ll examine how this adjusted operating margin compression shapes Amphastar’s investment narrative, particularly around cost control and operational...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data

MiroliverELAP trial update and why it matters for United Therapeutics (UTHR) United Therapeutics (UTHR) recently reported positive safety and survival findings from a phase 1 study of miroliverELAP, an external liver assist device for acute liver failure patients who are not eligible for transplants. The single arm, open label trial treated five such patients continuously for at least 44 hours. It met its primary survival endpoint during treatment and reported no unexpected serious adverse...
NasdaqGS:KE
NasdaqGS:KEElectronic

Kimball Electronics (KE) Margin Rebound Challenges Long Term Earnings Skepticism In Q2 2026

Kimball Electronics (KE) has put out a mixed Q2 2026 update, with revenue of US$341.3 million and basic EPS of US$0.15, alongside trailing twelve month EPS of US$0.98 on US$1.46 billion of revenue that reflects a sharp 199.5% earnings gain over the last year but a longer run of choppy results. The company has seen quarterly revenue move between US$341.3 million and US$380.5 million over the past six reported periods, while basic EPS has ranged from about US$0.13 to US$0.41. This sets the...
NYSE:MSI
NYSE:MSICommunications

What Motorola Solutions (MSI)'s New Role-Based AI Assist Suites Means For Shareholders

In late January 2026, Motorola Solutions launched Assist Suites, a portfolio of role-based AI tools that unify 911 audio, video, radio transcripts and other data to support faster emergency response, officer safety and more accurate reporting for public safety agencies. A key feature, Narrative Assist, cross-references an officer’s account with multiple verified data sources, highlighting discrepancies while preserving human oversight and a full audit trail, which could influence how...
NYSE:UNM
NYSE:UNMInsurance

Assessing Unum Group (UNM) Valuation After Recent Weak Momentum And Undervaluation Signals

Why Unum Group (UNM) Is On Investors’ Radar Today Unum Group (UNM) is drawing fresh attention after recent share price moves, with the stock showing negative returns over the past week, month, and past 3 months, and a modest positive total return over the past year. See our latest analysis for Unum Group. At a share price of US$75.66, Unum Group’s recent 7 day and 90 day share price returns of 0.83% and 3.19% declines contrast with a 1 year total shareholder return of 0.99% and very strong 3...
NYSE:EW
NYSE:EWMedical Equipment

Edwards Lifesciences Nears SAPIEN M3 Decision As Big Money Moves

Edwards Lifesciences (NYSE:EW) is awaiting an FDA decision on its SAPIEN M3 Transcatheter Mitral Valve Replacement system, a potential milestone for its structural heart portfolio. Institutional investors have been building positions around this catalyst, with recent order flow suggesting heightened attention on the upcoming regulatory outcome. The company has also been active with a share repurchase program, signaling confidence from management in the long term outlook. Edwards...